Nantkwest Inc (NASDAQ:NK) Short Interest Down 24.6% in March

Nantkwest Inc (NASDAQ:NK) saw a significant drop in short interest in the month of March. As of March 13th, there was short interest totalling 2,005,900 shares, a drop of 24.6% from the February 27th total of 2,660,000 shares. Based on an average daily volume of 762,800 shares, the short-interest ratio is currently 2.6 days. Approximately 22.0% of the company’s shares are sold short.

A number of equities analysts have recently commented on NK shares. ValuEngine raised shares of Nantkwest from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. BidaskClub downgraded shares of Nantkwest from a “buy” rating to a “hold” rating in a research note on Thursday, March 12th. Finally, Zacks Investment Research raised shares of Nantkwest from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Saturday.

A number of large investors have recently modified their holdings of NK. Credit Suisse AG bought a new stake in Nantkwest in the 4th quarter valued at about $480,000. Tower Research Capital LLC TRC raised its position in shares of Nantkwest by 4,218.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 47,766 shares of the biotechnology company’s stock worth $58,000 after buying an additional 46,660 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Nantkwest by 2.5% during the 4th quarter. Renaissance Technologies LLC now owns 1,634,925 shares of the biotechnology company’s stock worth $6,196,000 after buying an additional 39,200 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Nantkwest by 29.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 164,703 shares of the biotechnology company’s stock worth $625,000 after buying an additional 37,660 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Nantkwest by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 288,634 shares of the biotechnology company’s stock worth $1,093,000 after buying an additional 27,216 shares in the last quarter. Hedge funds and other institutional investors own 5.85% of the company’s stock.

NK stock traded down $0.32 during mid-day trading on Friday, hitting $3.15. 487,484 shares of the company were exchanged, compared to its average volume of 763,519. The company has a market capitalization of $341.74 million, a PE ratio of -4.44 and a beta of 2.76. The company has a current ratio of 4.82, a quick ratio of 5.72 and a debt-to-equity ratio of 0.09. Nantkwest has a twelve month low of $0.95 and a twelve month high of $9.90. The firm has a fifty day simple moving average of $4.78 and a 200 day simple moving average of $3.15.

Nantkwest (NASDAQ:NK) last posted its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.04. Nantkwest had a negative net margin of 152,997.67% and a negative return on equity of 45.71%. The company had revenue of $0.01 million for the quarter. As a group, sell-side analysts anticipate that Nantkwest will post -0.34 earnings per share for the current year.

Nantkwest Company Profile

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Featured Article: What is the role of the G-20?

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.